Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 418 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Immuneering Corporation | IMRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.68% | 1.47 | 05:26:53 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.48 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 5 | 418 | - | 1.38 - 11.92 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 04:31:21 | 1 | US$ 1.47 | USD |
Immuneering Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 43.34M | 29.28M | - | 0 | -53.47M | -1.83 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Immuneering News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.71 | 1.73 | 1.38 | 1.50 | 415,237 | -0.24 | -14.04% |
| 1 Month | 2.72 | 2.74 | 1.38 | 1.95 | 517,871 | -1.25 | -45.96% |
| 3 Months | 5.48 | 7.68 | 1.38 | 2.59 | 772,409 | -4.01 | -73.18% |
| 6 Months | 5.15 | 8.89 | 1.38 | 2.95 | 393,395 | -3.68 | -71.46% |
| 1 Year | 11.01 | 11.92 | 1.38 | 4.04 | 237,564 | -9.54 | -86.65% |
| 3 Years | 19.50 | 33.99 | 1.38 | 7.46 | 143,692 | -18.03 | -92.46% |
| 5 Years | 19.50 | 33.99 | 1.38 | 7.46 | 143,692 | -18.03 | -92.46% |
Immuneering Description
| Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies. |
